New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.

Conservative supporters of government deregulation want to do away with state-imposed licensing requirements, a move genetic counselors say will harm patients.

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

The biopharma company, which is developing cell therapies for cancers and autoimmune diseases, said it will use the proceeds for working capital.

Ibex Prostate Detect is designed to help pathologists catch small and rare cancers in whole-slide images from tissue biopsies that they might've missed.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.